ALUNBRIG (brigatinib) tablets

ALUNBRIG is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. Brand Name: ALUNBRIG (brigatinib) tablets, for oral use Initial U.S. Approval: 2017

Home | brigatinib tablets

ALUNBRIG (brigatinib) tablets price in India and Overseas
ALUNBRIG (brigatinib) Tablets

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

ALUNBRIG (brigatinib) Tablets

Brigatinib is a small-molecule targeted cancer therapy. Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.

A drug used to treat adults with non-small cell lung cancer that has spread and is ALK positive. It is also being studied in the treatment of other types of cancer. Alunbrig blocks certain proteins made by the ALK gene. Blocking these proteins may stop the growth and spread of cancer cells. Alunbrig is a type of tyrosine kinase inhibitor. Also called brigatinib.

Brigatinib, sold under the brand name Alunbrig among others, is a small-molecule targeted cancer therapy being developed by Ariad Pharmaceuticals, Inc. Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.

Drug (Brand / Generic): ALUNBRIG / brigatinib
Current Indications: non-small cell lung cancer
Marketed by:: Takeda Pharmaceutical Company Limited
Approval Date: 2017

Dosage forms and strengths of ALUNBRIG (brigatinib).
Tablets: 180 mg, 90 mg, or 30 mg.

Find Reference Updates

For ALUNBRIG (brigatinib) tablets Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions.

FDA News Release: FDA approves new oral therapy to treat ALK-positive lung cancer, December 2015.

EMA. Human Medicines: Xalkori (crizotinib), cited June 2017

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.